Harvard Cancer Center
Dr. Carlos Rodríguez-Galindo, a Spanish native, graduated from Autonomous University of Barcelona, Spain. Dr. Rodriguez-Galindo did his training in Pediatrics at the "Vall d’Hebron’s Children’s Hospital", in Barcelona, and completed his training in Pediatric Hematology-Oncology at St. Jude Children’s Research Hospital. After 10 years as clinical researcher at St. Jude Children’s Research Hospital, in August 2009 he moved to Dana-Farber Cancer Institute and Children’s Hospital in Boston, where he is the Director of the Pediatric Solid Tumor Program, Medical Director of the Clinical and Translational Investigations Program, and Director of the Global Health Initiative in Pediatric Cancer and Blood Disorders. He is Associate Professor of Pediatrics at the Harvard Medical School.
Dr. Rodriguez-Galindo’s clinical research has been focused in retinoblastoma, bone sarcomas, histiocytic disorders and rare childhood cancers. He actively participates in the development of new therapeutic strategies in those areas, and also has a special interest in the study and development of new drugs. Dr. Rodriguez-Galindo has been the primary investigator of several studies at St. Jude, including the frontline retinoblastoma trial, and several phase I studies. Dr. Rodriguez-Galindo is the Chair of the Retinoblastoma and Rare Tumors Committee at the Children’s Oncology Group (COG) and the primary investigator of COG studies for nasopharyngeal carcinoma, adrenocortical carcinoma, and recurrent malignant germ cell tumors. He is also the President-Elect of the Histiocyte Society and co-PI of the frontline LCH-IV study. Dr. Rodriguez-Galindo is also actively involved in the development of pediatric oncology programs in developing countries, particularly Latin-America, Africa, and South East Asia.